SERMORELIN

$60.00
QUANTITY
1
BUNDLE & SAVE
Total (1 Vial)

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids of the natural GHRH sequence. It is studied for its role in stimulating the pituitary gland’s natural production and release of growth hormone, making it a key compound in endocrine, metabolic, and longevity-focused research. Each vial contains 60mg of high-purity Sermorelin, manufactured to strict quality standards and verified through third-party lab testing (COA available on request).

For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.

Product Description

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids of the natural GHRH sequence. It is studied for its role in stimulating the pituitary gland's natural production and release of growth hormone, making it a key compound in endocrine, metabolic, and longevity-focused research. Each vial contains 60mg of high-purity Sermorelin, manufactured to strict quality standards and verified through third-party lab testing (COA available on request).

For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.

Compound Information
MOLECULAR PROFILE
TypeSynthetic compound
CategoryResearch Compound
Purity≥99%
FormLyophilized powder
STORAGE REQUIREMENTS
Lyophilized (powder)

-20°C · 24+ months

Reconstituted

2–8°C · ~30 days

Certificate of Analysis

Third-party tested for purity and quality.

PURITY
0 %
Variant GLP3-RT 10mg
Lot # REF0001
Labeled 20mg
Actual 22.61mg
Tested APR 15, 2026

Coming soon

Research
New England Journal of Medicine

Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial

2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.

New England Journal of Medicine

Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial

2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.

New England Journal of Medicine

Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial

2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.

Related Research

Free shipping

on orders over $200

Discreet shipping

plain and unbranded packaging

Secure checkout

256-bit SSL

Researcher verification.
Lightning Peptides LLC sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.
By proceeding you affirm the statements above are true. Products are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S. Food and Drug Administration.

Not a researcher? Exit